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OBJECTIVE
Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined
FLCk+FLCl [cFLC]) are associated with adverse clinical outcomes and increased
mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2
diabetes.
RESEARCH DESIGN AND METHODS
In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC,
high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were mea-
sured. CVD events over 2 years were recorded and assessed using multiple logistic
regression.
RESULTS
cFLC levels were elevated signiﬁcantly in 29 of 352 (8%) patients with CVD events
during 2 years follow-up (50.7 vs. 42.8 mg/L; P = 0.004). In multivariate analysis,
elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3
[95% CI 1.3–8.2]; P = 0.012) and remained signiﬁcant after adjusting for age,
albumin-to-creatinine ratio, diabetes duration, or treatment.
CONCLUSIONS
cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that war-
rants further investigation.
Predicting risk of cardiovascular disease (CVD) in type 2 diabetes (1–3) using algo-
rithms achieves only moderate performance particularly in different ethnic popu-
lations (3). An association between increased polyclonal combined immunoglobulin
free light chain (cFLC, summated FLCk+FLCl) concentrations and increased all-
cause mortality has been reported (4,5); we assessed the potential of cFLC as a
marker of CVD outcomes in south Asian patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS
The United Kingdom Asian Diabetes Study was a cluster-randomized controlled trial
aimed at reducing cardiovascular risk in south Asian patients with type 2 diabetes
(6–8). The current study included 352 south Asian patients whose baseline fasting
serum samples were available. Detailed clinical history including treatment, CVD
history at baseline and over 2 years of follow-up, plus serum biochemistry at base-
line (HbA1c, lipids, and albumin-to-creatinine ratio [ACR]) were obtained. Serum
cFLC (Freelite; The Binding Site Group Ltd, Birmingham, U.K.) and hsCRP (Siemens,
Mu¨nchen, Germany) levels were measured.
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Baseline characteristics of patients
with and without a nonfatal or fatal
CVD event over 2 years of follow-up
were compared using the t test,
Mann–Whitney U test for nonnormally
distributed variables, and x2 test for cat-
egorical variables as appropriate. Fac-
tors with a P value ,0.1 were selected
for inclusion in multivariate modeling
using forward stepwise logistic regres-
sion analysis to identify signiﬁcant pre-
dictors of CVD events, estimating odds
ratio (OR) and 95% CIs. Intervention
thresholds deﬁned in other populations
may not be appropriate for south Asian
patients with type 2 diabetes (7,9), so
receiver operator characteristic (ROC)
analysis was used to determine the op-
timal prognostic value of individual risk
factors for nonfatal or fatal CVD events.
A simple risk score was generated by
summing numbers of elevated risk fac-
tors for each patient. Age, ACR (.2.5
mg/mmol in men and .3.5 mg/mmol
in women), diabetes duration, treat-
ment with insulin, statins, or ACE inhib-
itors were included individually as
confounding factors. Statistical analysis
was performed using SPSS v19 (IBM,
Armonk, NY).
RESULTS
Over 2 years, there were 7 fatal (myo-
cardial infarction, 2; heart failure, 2;
stroke, 2; and cardiac arrest, 1) and 23
nonfatal CVD events (angina, 10; myo-
cardial infarction, 4; heart failure, 3;
stroke, 2; and coronary artery bypass
graft, 4). CVD events were associated
with increased cFLC concentrations
(50.7 vs. 42.8 mg/L; P = 0.004), HbA1c
(9.2 vs. 8.0% [77 vs. 64 mmol/mol]; P =
0.035), ACR (4.5 vs. 0.8 mg/mmol; P =
0.034), and age (64 vs. 55 years; P =
0.007), but not hsCRP (4.5 vs. 3.6 mg/L;
P = 0.389). Patients with CVD events
had longer duration of diabetes (10 vs. 6
years; P = 0.011) and were more likely to
have previous history of CVD (34.5 vs.
15.1%; P = 0.008), treatment with insulin
(41.4 vs. 21.4%; P = 0.014), statins (72.4
vs. 43.7%; P = 0.003), and ACE inhibitors
(58.6 vs. 30.0%; P = 0.002).
The optimal concentrations for pre-
dicting CVD events in this population
(determined by ROC analysis) were
cFLC .57.2 mg/L, triglycerides .6.7
mmol/L, HbA1c .9.2% [77 mmol/mol],
and systolic blood pressure (SBP) .155
mmHg. In multivariate logistic regres-
sion analysis using these values and pre-
vious history of CVD, elevated cFLC (OR
3.25; P = 0.012), triglycerides (OR 18.30;
P, 0.001), and SBP (OR 3.62; P = 0.004)
were independently associated with
CVD events (Table 1, Model 1). cFLC,
triglycerides, and SBP remained signiﬁ-
cantly associated with CVD risk after in-
dividually adjusting for age (Table 1,
Model 2), abnormal ACR (Table 1, Model
2), and treatment with ACE inhibitors
(Table 1, Model 3) or statins (Table 1,
Model 4).
A risk score based on cFLC, triglycer-
ides, and SBP identiﬁed patients with
0 (reference), 1 OR = 5.7 (95% CI 2.1–
15.0; P = 0.001), or 2 OR = 15.4 (4.8–
49.3; P, 0.001) risk factors; no patients
were abnormal for all three risk factors.
A total of 23 (79%) patients with CVD
events were abnormal for at least one
risk factor. Individually, 13 (45%) pa-
tients with CVD events had elevated
cFLC, 12 (41%) had abnormal SBP, and
6 (21%) had abnormal triglyceride
concentrations.
CONCLUSIONS
To our knowledge, this is the ﬁrst report
of a speciﬁc association between cFLC
and increased risk of CVD events in
type 2 diabetes. Our results are consis-
tent with recent reports showing that
high cFLC levels were prognostic for
all-cause mortality where circulatory
disease was a predominant cause of
death (4,5). A number of factors are tra-
ditionally associated with CVD risk in
western European populations (1–3,7).
In our study, HbA1c, SBP, triglycerides,
and CVD history were all associated
with poor outcomes; however, only
cFLC, SBP, and triglycerides were inde-
pendently associatedwith increased risk
of CVD events. An association between
elevated hsCRP levels and increased car-
diovascular risk has been reported in Eu-
ropean populations (1,3). Although both
cFLC and hsCRP are elevated in south
Asians with type 2 diabetes (8,9), in
this study, we found that cFLC was a
better predictor of CVD risk than hsCRP.
Healthy south Asians have higher hsCRP
levels than white Europeans (9), so the
lack of association observed in our study
may simply reﬂect disease-speciﬁc and
ethnic variations and support the need
for more ethnic-speciﬁc studies.
In our study, the association between
cFLC and CVD outcome was unaffected
Table 1—Multivariate logistic regression analysis using categorical variables
Variable Model 1 Model 2 Model 3 Model 4
cFLC .57 mg/L 3.25 (1.29–8.19)* 3.18 (1.26–8.02)* 3.23 (1.29–8.19)* 2.64 (1.02–6.86)*
Triglycerides .6.7 mmol/L 18.30 (5.11–65.53)‡ 17.95 (5.01–64.29)‡ 18.30 (5.11–65.53)‡ 15.46 (4.15–57.63)‡
SBP .155 mmHg 3.62 (1.50–8.74)† 3.64 (1.51–8.81)† 3.62 (1.50–8.74)† 3.43 (1.39–8.47)†
HbA1c .9.2% [77 mmol/mol] NS NS NS NS
Prior history of CVD NS NS NS NS
Age .62 years d NS d d
Abnormal ACR d NS d d
ACE inhibitor treatment d d NS d
Statin treatment d d d 2.63 (1.02–6.77)*
Optimal cutoff values for cFLC, triglycerides, HbA1c, and SBP for predicting nonfatal or fatal CVD events in south Asian patients with type 2 diabetes
were determined using ROC analysis and included with CVD history in a forward stepwise logistic regression model (Model 1). ORs (95% CI) are
shown for each factor. NS indicates factors included in each model not associated with CVD events.d indicates factors not included in each model.
Model 1 was then adjusted in separate analyses for both age and abnormal ACR (Model 2), for ACE inhibitor therapy (Model 3), and for statin therapy
(Model 4). The ORs of models adjusted for insulin treatment or diabetes duration were the same as Model 1 (not shown). Factors that were
signiﬁcantly associated with adverse CVD outcomes are indicated. *P , 0.05. †P , 0.01. ‡P , 0.001.
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after adjusting for age or for diabetes
duration. However, diabetes occurs
at a younger age in south Asian popula-
tions (7), and age at diagnosis may be a
more appropriate risk marker than cur-
rent age (2). Furthermore, cFLC re-
mained independently associated with
CVD risk after adjustment for insulin,
statins, or ACE inhibitors. Although
these treatments have been successful
in reducing the risk of CVD in diabetes,
the residual risk remained signiﬁcant
and may result from elevated triglycer-
ide levels and chronic inﬂammation,
which have been proposed as additional
therapeutic targets (10,11). In this
study, a simple risk model including
cFLC, SBP, and triglycerides identiﬁed
the majority of patents suffering CVD
events and could therefore be useful in
identifying high-risk patients that may
beneﬁt from such novel treatments. Mi-
croalbuminuria is an important risk fac-
tor for CVDQ:2 (12). In this study, an
abnormal ACR was not independently
associated with CVD outcome and ad-
justing for abnormal ACR did not alter
the association of cFLC with CVD risk.
The lack of association between ACR
and CVD may simply reﬂect the aggres-
sive risk-factor management in those
with microalbuminuria but needs fur-
ther veriﬁcation.
Serum cFLC levels represent the bal-
ance between B-cell lineage production
and clearance/metabolism that occurs
principally in the kidneys (13,14). cFLC
concentrations are raised by chronic in-
ﬂammation or renal insufﬁciency
(13,14), which are both features of
type 2 diabetes. cFLC levels also corre-
late strongly with the severity of renal
impairment (15). Previous work from
our group demonstrated that cFLC con-
centrations are elevated in patients with
diabetes compared with healthy control
subjects and were seen before overt
signs of renal disease (8). Increasing
cFLC concentrations may therefore pro-
vide an early indication of CVD risk in
patients with diabetes (12).
While our study is limited by its size,
follow-up time, and few events, the con-
sistent association of cFLC with adverse
CVD outcomes suggests that cFLC could
be an important marker in the estima-
tion of CVD risk. Further studies
involving larger cohorts are needed to
examine the validity of these ﬁndings
in other ethnic groups and to determine
whether cFLC measurement would im-
prove existing risk models, such as
QRISK2 or the United Kingdom Prospec-
tive Diabetes Study (2). Further investi-
gations are also required to examine the
inﬂuence of factors such as obesity, hy-
pertension, and diabetes treatments on
cFLC concentrations. cFLC elevationmay
aid in the identiﬁcation of additional
therapeutic targets in patients with
high residual risk.
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